To compare therapeutic benefits of different immunophilin ligands for treating nerve injuries. Cyclosporine, FK506 and rapamycin, were evaluated first on a serum-free culture of embryonic dorsal root ganglia followed by a new model of chronic nerve compression. Outcomes of the study have shown a potent effect of cyclosporine and FK506, on dorsal root ganglia axonal outgrowth, comparable to the effect of nerve growth factor. Rapamycin exhibited only a moderate effect. The study revealed the beneficial effects of cyclosporine, FK506 and rapamycin for neuromuscular regeneration. Cyclosporine showed the better maintenance of the tissues and function. Cyclosporine, FK506 and rapamycin drugs showed potential for treating peripheral nerve chronic compression injuries.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/rme-2020-0130 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Characterisation and Profiling of Standard Atopic Dermatitis Therapies in a Chronic Dermatitis Murine Model Induced by Oxazolone.
Exp Dermatol
December 2024
Almirall R+D Centre, Almirall S.A, Sant Feliu de Llobregat, Spain.
Atopic dermatitis (AD) is a common inflammatory skin disorder characterised by hypersensitivity to allergens, eczematous lesions and pruritus. The aim of this study was to comprehensively characterise a murine model of dermatitis and assess the similarity with the human disease, as well as to profile clinically relevant AD therapies. Four repeated topical administrations of oxazolone in the auricular skin of sensitised mice induced morphological features compatible with AD, including redness and swelling, as well as histological changes typical of spongiotic (eczematous) dermatitis and increased plasmatic IgE.
View Article and Find Full Text PDFEnglish version of clinical practice guidelines for the management of atopic dermatitis 2024.
J Dermatol
December 2024
Medical Informatics and Management, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
This is the English version of the 2024 clinical practice guidelines for the management of atopic dermatitis (AD). AD is a disease characterized by relapsing eczema with pruritus as a primary lesion. A crucial aspect of AD treatment is the prompt induction of remission via the suppression of existing skin inflammation and pruritus.
View Article and Find Full Text PDFThrombotic Microangiopathy Associated with Calcineurin Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data.
Clin Ther
December 2024
Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China. Electronic address:
Purpose: Calcineurin inhibitors (CNIs) are currently the first-line drugs for preventing and treating post-transplant rejection in organ transplant recipients. However, these drugs, especially tacrolimus, have the potential to induce thrombotic microangiopathy (TMA), a rare but potentially fatal complication that can develop following transplantation. This condition has garnered considerable attention within the medical community.
View Article and Find Full Text PDFEfficacy and safety of nine immunosuppressive agents for primary focal segmental glomerulosclerosis in adults: a pairwise and network meta-analysis.
Ren Fail
December 2024
Department of Nephrology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, P. R. China.
Background: Immunosuppressants are widely used as the preferred treatment for primary focal segmental glomerulosclerosis (pFSGS). Nevertheless, controversies persist regarding the effectiveness and side effects of different immunosuppressive medications.
Methods: From July 2023 until June 2024, we systematically searched PubMed, Cochrane Library, Web of Science, clinicalrials.
Belumosudil in pediatric patients with chronic graft-versus-host disease after failed multi-line therapy: a case series.
Ann Hematol
December 2024
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Belumosudil is a selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2) indicated for patients with glucocorticoid-refractory chronic graft-versus-host disease (cGVHD). Despite its approval for ages 12-18, there is limited pediatric data available. This case series presents three 12-year-old patients with severe cGVHD who had failed multiple lines of therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!